BIVI•benzinga•
BioVie Enrolls First Patient In Phase 2 ADDRESS-LC Clinical Trial Evaluating Bezisterim For Treatment Of Neurological Symptoms Associated With Long COVID; Expects Topline Data To Be Available In H1 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga